155 related articles for article (PubMed ID: 7587043)
21. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Dresser LD; Niederman MS; Paladino JA
Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
[TBL] [Abstract][Full Text] [Related]
22. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.
Oosterheert JJ; Bonten MJ; Schneider MM; Buskens E; Lammers JW; Hustinx WM; Kramer MH; Prins JM; Slee PH; Kaasjager K; Hoepelman AI
BMJ; 2006 Dec; 333(7580):1193. PubMed ID: 17090560
[TBL] [Abstract][Full Text] [Related]
24. [Community acquired pneumonia: from intravenous to oral cephalosporin sequential therapy].
Fernández P; San Martín L
Rev Med Chil; 2000 Mar; 128(3):267-72. PubMed ID: 10962867
[TBL] [Abstract][Full Text] [Related]
25. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.
Nathan RV; Rhew DC; Murray C; Bratzler DW; Houck PM; Weingarten SR
Am J Med; 2006 Jun; 119(6):512.e1-7. PubMed ID: 16750965
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
27. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
28. Containing costs and containing bugs: are they mutually exclusive?
Nicolau DP
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S12-7. PubMed ID: 19236136
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
30. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
31. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Samsa GP; Matchar DB; Harnett J; Wilson J
Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
[TBL] [Abstract][Full Text] [Related]
32. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.
Stein GE; Mantz SL
Hosp Pharm; 1995 Feb; 30(2):132-4, 137. PubMed ID: 10140526
[TBL] [Abstract][Full Text] [Related]
33. Clinical and economic outcomes of empiric parenteral antibiotic therapy for pneumonia: a retrospective study of 1,032 hospitalized patients.
Bassi O; Zuccarelli S; Amalfitano ME
J Chemother; 1998 Oct; 10(5):369-74. PubMed ID: 9822354
[TBL] [Abstract][Full Text] [Related]
34. [Duration of treatment and oral administrad on of antibiotics in community acquired pneumonia].
Bernal-Vargas MA; Cortés JA
Rev Chilena Infectol; 2016 Apr; 33(2):177-86. PubMed ID: 27314995
[TBL] [Abstract][Full Text] [Related]
35. How short can courses be in lower respiratory tract infections?
Siegel R
J Int Med Res; 2000; 28 Suppl 1():37A-47A. PubMed ID: 11092228
[TBL] [Abstract][Full Text] [Related]
36. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
Balfour JA; Benfield P
Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
[TBL] [Abstract][Full Text] [Related]
37. Community-acquired pneumonia: is it time to shorten the antibiotic treatment?
Esposito S; Fiore M
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):933-8. PubMed ID: 18039078
[No Abstract] [Full Text] [Related]
38. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
[TBL] [Abstract][Full Text] [Related]
39. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia.
Opmeer BC; El Moussaoui R; Bossuyt PM; Speelman P; Prins JM; de Borgie CA
J Antimicrob Chemother; 2007 Nov; 60(5):1131-6. PubMed ID: 17827142
[TBL] [Abstract][Full Text] [Related]
40. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
